Recombinant anti-CD4 antibodies for human therapy

Details Recombinant anti-CD4 antibodies for human therapy Recombinant anti-CD4 antibodies for human therapy

2000-07-10

2008-11-18

Yaen, Christopher H (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Reexamination Certificate

active

07452534

ABSTRACT:
Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).

REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4975369 (1990-12-01), Beavers et al.
patent: 4978745 (1990-12-01), Schoemaker et al.
patent: 5750105 (1998-05-01), Newman et al.
patent: 5756096 (1998-05-01), Hanna et al.
patent: 2003/0077275 (2003-04-01), Hanna et al.
patent: 0451216 (1991-10-01), None
patent: 0 523 949 (1992-07-01), None
patent: 0523949 (1993-01-01), None
patent: 0 682 040 (1995-11-01), None
patent: 0682040 (1995-11-01), None
patent: 1 266 965 (2002-12-01), None
patent: 1266965 (2002-12-01), None
patent: 1 266 965 (2003-01-01), None
patent: 1266965 (2003-01-01), None
patent: WO 88/07089 (1988-09-01), None
patent: 9008198 (1990-07-01), None
patent: WO 90/08198 (1990-07-01), None
patent: WO 90/15152 (1990-12-01), None
patent: WO 93/02108 (1993-02-01), None
Ren EC (Ann Acad Med Singapore Jan. 1991;20(1):66-70).
Jones, P.T. et al., Nature, 321:522, (1986).
Camerini, D. and Seed, B., Cell, 60:747, (1990).
McClure, M.O. et al., Nature 330:487, (1987).
Truneh, A. et al., Cell. Immun., 131:98, (1990).
Nishimura, Y. et al., Cancer Research, 47:999 (1987).
Ward, E.S. et al., Nature, 341:544 (1989).
Camerini, D. and Seed, B., Abstract No. T.C.P. 125, V International Conference on AIDS, p. 587, (1989).
Persson et al., Proc. Natl. Acad. Sci. USA, 88:2432, 1991.
Meek et al., J. Immun., 146:2434, 1991.
Allison et al., J. Immunological Methods, 95:157, 1986.
Ehrlich et al., Hybridoma, vol. 7, No. 4, pp. 385-395, 1988.
Ehrlich et al., Clin. Chem., 34:1681, 1988.
Van Meel et al., J. Immunological Methods, 80:267, 1985.
BS Heteromycloma line, abstract.
Ehrlich et al., Hum. Antibod. Hybridomas, 1990, vol. 1, No. 1.
Ehrlich et al., Hybridoma, vol. 6, No. 2, pp. 151-160, 1987.
Herpes Transformation, abstract.
Amoroso et al., J. Immun., 145:3155, 1990.
Huse et al., Science, 246:1275, 1989.
Letvin, et al., Effect of Recombinant Soluble CD4 in Rhesus Monkeys Infected With Simian Immunodeficiency Virus of Macaques, Abstract from the V Int. Conf. on AIDS, 1989, p. 535.
Rosenberg, M. et al.,Biotherapy, “Soluble recombinant CD4—A potential therapeutic agent for HIV infector”, 2:107, (1990).
Reichmann, L. et al.,Nature, “Reshaping human antibodies for therapy”, 332:323-327, (1988).
Houghton, A.N. et al.,Seminars in Oncology, “Monoclonal antibodies potential applications to the treatment of cancer”, 13:165, (1986).
Watanabe, M. et al., Proceedings of the National Academy of Sciences, 88:4616-4620, (1991).
Van Meurz et al. Journal Of Immunological Methods (1986) 123.
Morrison Science, vol. 229, 1202 (1985).
Immunology Today 10:253 (1989).
Queen et al., PNAS 8610029 (1989).
Waldmann Science, vol. 252, 1657, (1991).
Hied et al., Genes and cancer (1990) p. 183.
Vopr Virusol, vol. 30, No. 5, issued Oct. 1985, Markova et al., “Monkey B lymphocyte subpopulations transformed by baboon herpes virus in vivo and in tissue cultures”, pp. 549-553.
Harris et al., T.B. Tech., vol. 11, p. 42 (1993).
Truneh et al., “Humoral Response of Cynomolgus Macaques to Human Soluble CD4: Antibody Reactivity Restricted to Xeno-Human Determinants” Cellular Immunology, Nov. 1990, vol. 131, No. 1, pp. 98-108.
Van Meurs et al. “Production of Primate Monoclonal Antibodies” Journal Of Immunological Methods, 1986, vol. 95, pp. 123-128.
Schroeder et al. “Early Restriction of the Human Antibody Repertoire” Science, Nov. 6, 1987, vol. 238, pp. 791-793.
Combriato et al. “V Lambda and J Lambda-C Lambda Gene Segments of the Human Immunoglobulin Lambda Light Chain Locus are Separated by 14 KB and Rearrange by a Deletion Mechanism” European Journal Of Immunology, Jun. 1991, vol. 21, pp. 1513-1522.
Hughes-Jones et al. “Nucleotide Sequences and Three Dimensional Modelling of the VH and VL Domains of Two Human Monoclonal Antibodies Specific for the D Antigen of the Human RH-Blood Group System” The Biochemical Journal, May 15, 1990, vol. 268, No. 1, pp. 135-140.
Stephens et al., “Antibodies are Produced to the Variable Regions of the External Envelope Glycoprotein of Human Immunodeficiency Virus Type 1 in Chimpanzees Infected with the Virus and Baboons Immunized with a Candidate Recombinant Vaccine” The Journal Of General Virology, May 1992, vol. 73, No. 5, pp. 1099-1106.
Combriato, G., et al., Vλ and Jλ -Cλ gene segments of the human immunoglobulin λ light chain locus are separated by 14 kb and rearrange by a deletion mechanism,Eur. J. Immunol. 21:1513-1522 (1991).
Houghton, A., et al., Monoclonal antibodies: potential applications to the treatment of cancer,Seminars in Oncology, 13(2):165-179 (1986).
Hughes-Jones, N., et al., Nucleotide sequences and three-dimensional modelling of the VHand VLdomains of two human monoclonal antibodies specific for the D antigen of the human Rh-blood-group system,Biochem. J. 268:135-140 (1990),
Riechmann, L., et al., Reshaping human antibodies for therapy,Nature332(6162):323-327 (Mar. 24, 1988).
Schroeder, H., et al., Early restriction of the human antibody repertoire,Science, New Series, 238(4828):791-793 (Nov. 6, 1987).
Stephens, D.M., et al., Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine,Journal of General Virology, 73:1099-1106 (1992).
Truneh, A., et al., Humoral response of cynomolgus macaques to human soluble CD4: antibody reactivity restricted to xeno-human determinants,Cellular Immunology131:98-108 (1990).
Van Meurs, G.J.E., et al., Production of primate monoclonal antibodies,Journal of Immunologial Methods, 95:123-128 (1986).
Watanabe, M., et al., Immunization of simian immunodeficiency virus-infected rhesus monkeys with soluble human CD4 elicits an antiviral response,Proc. Natl. Acad. Sci. USA, 88:4616-4620 (Jun. 1991).
Proceedings of the National Academy of Sciences USA, vol. 88, No. 1, issued Jan. 1, 1991, Watanabe et al., “Soluble human CD4 elicits an antibody response in rhesus monkeys that inhibit simian immunodeficiency virus replication”, pp. 120-124, see abstract.
Surg. Cynecol. Obstet., vol. 166, No. 1, Delmonico et al., “Monoclonal antibody treatment of human allograft recipients”, pp. 89-98, see Abstract.
Infection and Immunity, vol. 61, No. 10, issued Oct. 1993, Lopez-Guerro et al., “Modulation of adjuvant arthritis in Lewis rats by recombinant vaccinia virus expressing the human 60-kilodalton heat shock protein”, pp. 4225-4231, see entire document.
Dev. Comp. Immunol. vol. 17, No. 6, issued Nov.-Dec. 1993, Lewis et al. “Cloning and sequence analysis of kappa and gamma cynomolgus monkey immunoglobulin cDNAs”, 549-560.
Biotechnology, vol. 10, No. 11, issued Nov. 1992, Newman et al, “Primatization” of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against CD4, pp. 1455-1460.
Jones, P.T. et al., Nature 321:522 (1986).
Camerini, D. and B. Seed, Cell 60:747 (1990).
McClure, M.O. et al., Nature 330:487 (1987).
Truneh et al., “Humoral Response of Cynomolgus Macaques to Human Soluble CD4: Antibody Reactivity Restricted to Xeno-Human Determinants” Cellular Immunology 131:1 (Nov. 1990) pp. 98-108.
Nishimura, Y et al., Cancer Research 47:999 (1987).
Ward, E.S. et al., Nature 341:544 (1989).
Camerini, d. and B. Seed, Abstract No. T.C.P. 125, V Intern

Affiliated with

Also associated with

Rating

Recombinant anti-CD4 antibodies for human therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant anti-CD4 antibodies for human therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant anti-CD4 antibodies for human therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4029646